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Analysis of genetic variation in 16 varicella-zoster
virus (VZV) isolates selected at random and
circulating in the Irish population betweenMarch
2002 and February 2003was carried out. A 919 bp
fragment of the glycoprotein E gene (open read-
ing frame 68) encompassing codon 150, at which
a non-synonymous mutation defines the escape
mutant VZV-MSP, and including two other epi-
tope regions e1 and c1, was sequenced. No new
single nucleotide polymorphisms (SNPs) were
detected, indicating stability of these epitopes in
clinical isolates of VZV. However, when four
informative polymorphic markers consisting of
defined regions from genes 1, 21, 50, and 54
were sequenced 14 variable nucleotide positions
were identified. Phylogenetic analysis showed
the presence of three highly supported clades A,
B, and C circulating in the Irish population.
Approximately one third (6/16; 37.5%) of the Irish
VZV isolates in this study belonged to genotype
C, 4/16 (25%) to genotype A, and 4/16 (25%)
to genotype B. A smaller number 2/16 (12.5%)
belonged to genotype J1. This indicates remark-
able heterogeneity in the Irish population given
the small sample size. No evidence was found to
suggest anyof the 16 isolateswas a recombinant.
Thesefindingshave implications for themodel of
geographic isolation of VZV clades to certain
regions as the circulating Irish VZV population
appears to comprise approximately equal num-
bers of each of the main genotypes. This data is
inconsistent with a model of strict geographical
separation of VZV genotypes and suggests that
VZVdiversity ismorepronounced incertainareas
thanhadbeen thoughtpreviously.J.Med.Virol.
73:131–136, 2004.  2004 Wiley-Liss, Inc.
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INTRODUCTION
Varicella-zoster virus (VZV) is a member of the a-
herpesvirus subfamily of Herpesviridae. It is the
aetiological agent of chickenpox (varicella) in childhood,
after which the virus enters a latent state in the sensory
ganglia; decades later, the same virus may reactivate to
cause shingles (zoster). The VZV genome is a 125 kb
linear double-stranded DNA molecule and encodes
approximately 71 gene products [Davison and Scott,
1986]. VZV is an extremely stable virus. The nucleotide
diversity of VZV has been estimated at 0.00063 which is
similar to the human genome (0.00078) and at least five
times less than that of any other member of the human
herpes virus family [Barrett-Muir et al., 2002]. This low
rate of divergence probably reflects the few replicative
cycles VZV undergoes during its life cycle in the host.
However, genetic diversity among strains of VZV has
been demonstrated. This genetic variation, predomi-
nantly a result of single nucleotide polymorphisms
(SNPs), has been defined by the presence or absence of
restriction sites, such as aPstI site in gene 38 and aBglI
site in open reading frame (ORF) 54, and also by an
alteration in the number of repeat elements within the
five repeat region in the VZV genome [Adams et al.,
1989; Hondo et al., 1989; Takayama et al., 1996]. These
features were used to distinguish the live attenuated
Japanese Oka vaccine and wild type viruses circulating
in the United States and United Kingdom [LaRussa
et al., 1992; Hawrami et al., 1996]. Furthermore, a
mixture of genetically distinct strains were shown to be
circulating in the East End of London (United King-
dom), where 20% of VZV strains were positive for a BglI
restriction site in gene 54 [Hawrami et al., 1997].
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However, 60% of strains from zoster presenting in
immigrants whose primary infection occurred in the
Indian subcontinent, Africa, and the Caribbean were
BglI positive as compared with only 10% of viruses
from cases of zoster in patients brought up in the
United Kingdom. Recently a heteroduplex mobility
assay (HMA)was used to identify variants of VZV circu-
lating in the United Kingdom and elsewhere [Barrett-
Muir et al., 2001, 2002]. Polymorphisms identified by
HMA were confirmed and characterised by nucleotide
sequence analysis, allowing identification of additional
SNPs which can be used to genotype VZV strains.
Furthermore, phylogenetic analysis distinguished at
least three major clades (A, B, and C) among VZV
isolates collected worldwide [Barrett-Muir et al., 2003].
Variation in the VZV genotype appeared to be asso-
ciated closely with the geographical region in which
infection was acquired, with strains in clade A forming
anAfrican–Asian grouping, whereas strains in clades B
and C were found mainly in European populations.
Little is known about differences in properties of
different strains of wild type VZV viruses. However, a
mutation in a functionally important gene may have
dramatic effects on biological and clinical phenotype.
In 1998, aVZVmutant virus (VZV-MSP)was discovered
in Minneapolis-St. Paul, Minnesota; the virus had a
missense mutation in the preponderant surface glyco-
protein called gE [Santos et al., 1998]. A SNP (G>A) in
codon 150 of ORF 68 resulted in an amino acid change of
aspartic acid to asparagine. Thismutation led to a lostB-
cell epitope in the gE ectodomain. Furthermore the
mutant virushada recognisable phenotype consisting of
accelerated cell spread inboth cell culture and theSCID-
hu (severe combined immunodeficient mouse with a
human skin implant)model of VZV pathogenesis aswell
as a different pattern of egress, as shown by scanning
electronmicroscopy [Santos et al., 2000]. Theprevalence
and clinical significance of the mutation in this epitope
is unknown. Therefore we examined clinical isolates of
VZV collected in the Republic of Ireland for this
mutation. We also investigated genetic variation in
these VZV isolates by SNP analysis using a representa-
tive subset of gene markers. Our findings have implica-
tions for the association of VZV clades to specific
geographical regions.
MATERIALS AND METHODS
Patients and Clinical Samples
Isolates of VZV from 16 Irish patients were analysed.
All samples were collected as swabs of vesicle fluid in
viral transport medium between March 2002 and
February 2003, and processed in the National Virus
Reference Laboratory, University College, Dublin.
There was no epidemiological relationship, either in
time or place, between the patients. All cases of varicella
were sporadic. Specimens were collected from patients
with varicella at least 8 weeks apart and from different
regions of the country. Clinical characteristics of these
patients were reviewed. Varicella was defined as vesi-
cular eruption with a generalised onset and no derma-
tomal distribution. Herpes zoster was defined as the
appearance of typical vesicular skin lesions with a
dermatomal distribution. Disseminated herpes zoster
consisted of six skin lesions beyond the boundaries of the
primary dermatome and/or visceral involvement.
VZV DNA Isolation and Polymerase
Chain Reaction
VZV DNA was isolated from 200 ml of virus infected
cells using theQIAampDNAMiniKit (Qiagen,Crawley,
United Kingdom) according to the manufacturer’s
instructions. DNA amplification reactions were carried
out in 50 ml volumes with 1 ml of extract or control DNA,
2.5 U of HotStarTaq DNA polymerase (Qiagen), 1 mM of
each forward and reverse primer, 200 mM concentra-
tions of each deoxynucleoside triphosphate, and 1.5mM
MgCl2. Thermal cycling comprised an initial hot start at
958C for 15 min, followed by 35–40 cycles of 948C for
1 min, 558C for 1 min, and then 728C for 1 min, with a
final extension step at 728C for 10 min. The PCR
products were visualized on an UV transilluminator
following agarose gel electrophoresis in 2% (w/v) gels
containing 0.5 mg ethidium bromide ml1 in 0.5 Tris-
borate-EDTA running buffer. To assess the MSP status
of the clinical samples a 919 bp fragment of the gE gene
(ORF68)was amplifiedusing primerpairs, gE-FandgE-
R (Table I) [Shankar et al., 2001]. In addition, informa-
tive polymorphic markers from VZV genes 1, 21, 50,
and 54 were employed for genotyping and these amplify
TABLE I. Oligonucleotide Primers Used to Amplify and Sequence Genes in Varicella-Zoster Virus (VZV) Isolates
Primer Sequence (50–30)
Nucleotide
position
Amplicon
size (bp) Reference
GE-F TCACACCGATGAAGACAAAC 115921–115940
GE-R CCACATATGAAACTCAGCCC 116839–116820 919 Shankar et al. [2001]
VZV-1F TCAGCTGGCTTTTCTAAGAATTCG 427–450
VZV-1R TATTTTTGGGATCCGCAATGTC 932–911 506 Barrett-Muir et al. [2002]
VZV-21F TAATGAATTGAGGCGCGGTTTA 33497–33518
VZV-21R CACGTGTAGCTCCAAAAACCTAGG 33999–33976 503 Barrett-Muir et al. [2002]
VZV-50F CGCACCCAAAGTGAACATCAT 87736–87756
VZV-51R TCTCGGATGTCAAATATGTTACGA 88250–88227 515 Barrett-Muir et al. [2002]
VZV-54BgIIFþ CGTAATGCATAACAGGCCAACAC 95005–95027
VZV-54BgIIRþ GAAACCTGGCGTCAAACATTACA 95501–95479 497 Barrett-Muir et al. [2002]
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500 bp fragments of the VZV genome (Table I) [Barrett-
Muir et al., 2002]. Oligonucleotide primers were man-
ufactured by Sigma-Genosys (Sigma-Genosys, Cambs,
UnitedKingdom) andPCRproducts were purified using
a MinElute PCR purification kit (Qiagen).
DNA Sequencing and Phylogenetic Analysis
Automated DNA sequencing was carried out on an
ABI Prism 3730XL DNA Analyser (Perkin Elmer
Applied Biosystems, UK, Warrington, UK). Sequencing
reactions of purified PCR products were performed in a
20 ml reaction volume containing 8 ml of the Big Dye
terminator mix (version 3.1 Chemistry), 3.2 pmol of the
forward primer, and 100 ng of PCR product template.
The GenAmp PCR system 9600 was programmed for
5 min at 968C, then 25 cycles of 968C for 30 sec, 508C for
15 sec, 558C for 4 min. The extension products were
purified on spin columns, dried down, and resuspended
in template suppression buffer (Perkin Elmer). Sequ-
ence traces were analysed using Chromas v. 1.45 DNA
software (ConorMcCarthy, Griffith University, Austra-
lia) and sequence polymorphisms identified by ClustalX
alignment [Thompson et al., 1997] with the relevant
regions of the Dumas vaccine strain [Davison and Scott,
1986]. A multiple alignment containing four gene
regions (ORFs1, 21, 50, and54) in order,was assembled,
aligned, and optimised usingMacClade 4.03 [Maddison,
2001]. Phylogenetic reconstructions, employing max-
imum parsimony and maximum likelihood, were carri-
ed out using PAUP* 4.0b10 [Swofford, 1998] with the
Dumas sequence employed as outgroup. A heuristic
search strategy was employed using random sequence
addition with ten replicated and TBR branch swapping
in effect. The model of evolution for likelihood analysis
was chosen using Modeltest version 3.06 [Posada and
Crandall, 1998]. The chosen model of evolution (K80)
included two substitution types with the transition
transversion ratio estimated at 14.0, no rate variation
across sites, and equal base frequencies. Model para-
meters were then estimated using a heuristic search
strategy and selecting those with the highest likelihood.
Bootstrappingwasemployed to examine tree robustness
under both methods with 1000 replicates performed.
The following accession numbers have been assigned:
GenBank entry for genotype C1 (SNP95118) (VZV ORF
54) is AY379115, and GenBank entry for genotype B1
(SNP95241) (VZV ORF 54) is AY379116.
RESULTS
All 16 patients from whom VZV was isolated were
Irish (Table II). Five patients presented with varicella,
whereas 11 had herpes zoster, of whom one had cuta-
neous dissemination. No visceral disseminations were
observed, even among immunocompromised patients,
and no death was related to VZV infection. The mutant
strain VZV-MSP, associated with increased virulence
in an animal model, was not detected in any of the 16
clinical isolates. However, one polymorphism, the
synonymous nucleotide substitution of T>C at codon
220 in ORF68 (SNP116467; Table III), was identified
in the epitope-encoding region of the gE gene in eight
isolates.
To determine thedistribution of genotypes in the Irish
VZV isolates a subset of informative polymorphic
markers in ORFs 1, 21, 50, and 54 were analysed. The
results of the phylogenetic analysis and genotyping are
shown in Figure 1 and Table III, respectively. Signi-
ficant genetic diversity, including new genotypes were
identified among these isolates (Table III). Approxi-
mately one third 6/16 (37.5%) of the Irish VZV isolates
in this study belonged to genotype C, 4/16 (25%) to
genotype A, and an equal number were genotype B 4/16
(25%). A smaller number 2/16 (12.5%) belonged to geno-
type J1. Three trees were produced under parsimony
each differing only in the relative positions of sequences
belonging to B and B1 genotypes (Fig. 1). Relationships
TABLE II. Characteristics of VZV Infections in Irish Patients From Whom VZV Was Isolated Between March 2002 and
February 2003
VZV isolate Sex Age (years) Nationality Immunocompromised
Varicella (V)
or zoster (Z) History of varicella
01 M 82 Irish — Z Childhood in Ireland
02 M 4 Irish — V —
03 F 53 Irish Yes Z Childhood in Ireland
04 M 1 Irish — V —
05 F 71 Irish Yes Z NA
06 M 31 Irish Yes Za Childhood in Ireland
07 F 61 Irish — Z NA
08 M 61 Irish — Z NA
09 M 70 Irish — Z NA
10 F 34 Irish Yes Z Childhood in Ireland
11 M 61 Irish — Z NA
12 F 5 Irish — V —
13 M 5 Irish — V —
14 M 1 Irish — V —
15 M 75 Irish — Z —
16 M 74 Irish — Z Childhood in Ireland
NA, not available.
aDisseminated cutaneous zoster.
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present under parsimony were highly congruent to
those seen under likelihood fromwhich a single treewas
produced. Genotypes A, B, and C were separated under
both methods with high bootstrap support (>90 BP,
BP¼bootstrap proportion). While bootstrap support
for genotype A was not unimpeachable (<70 BP) the
presence of a Sau96I restriction site in ORF 21 (SNP
33646) further subdivided isolates of this genotype into
A1 andA2 (Fig. 1). Genotype J1wasmore closely related
to genotype A than genotypes B and C falling into the
same highly supported clade. Furthermore, two geno-
types not reported previously were also identified. A
synonymous G>A mutation in ORF 54 (SNP 95118)
subdivided clade C viruses into genotype C and the new
genotype C1, and a T>Gmutation (SNP 95241) in ORF
54 subdivided clade B viruses into B and the new
genotype, B1 (Fig. 1 and Table III). Bootstrap support
for these divisions was <70 BP and the separation of
genotypesBandB1wasnot supportedbyparsimony.No
evidence was found to indicate that any of the
VZV isolates circulating in the Irish population was a
recombinant.
DISCUSSION
The data presented in this study using informative
polymorphicmarkers in genes 1, 21, 50, and 54 show the
high degree of heterogeneity among VZV isolates
Fig. 1. Phylogenetic reconstruction of Irish varicella-zoster virus
(VZV) sequences under maximum likelihood. Numbers on the bran-
ches represent bootstrap proportions (BP) under likelihood while
those beneath the branches represent BPs under parsimony
(1000 replicates).
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circulating in Ireland between March 2002 and Febru-
ary 2003. Previous SNP analyses of this kind have
shownremarkable geneticuniformity ofVZV isolates, as
for example in the African/Asian regions of the world,
where genotype A predominates [Barrett-Muir et al.,
2002]. In contrast, VZV populations in the United
Kingdom and Brazil were more heterogeneous with
strains of the threemain genotypesA, B, andC [Barrett-
Muir et al., 2002, 2003]. Themajority of viruses from the
UnitedKingdomwere genotype C,whereas among Irish
isolates therewere almost equal proportions of themain
genotypesA,B, andC, at 25, 25, and37.5%, respectively.
Furthermore, two isolates were genotype J1, only re-
ported previously in Japanese samples [Barrett-Muir
et al., 2002].Evenmore surprisingwas thefinding of two
novel genotypes derived from cladesB andC, namelyB1
and C1, respectively. It has been suggested that the
mixture of viruses in the United Kingdom related to the
pattern of immigration to those countries [Barrett-Muir
et al., 2003]. This hypothesis is supported by the recent
spread in London of clade A strains, which appeared to
coincide with immigration from Africa and the Indian
subcontinent to the United Kingdom [Hawrami et al.,
1997]. In our study, all patients were Irish. However,
three of the patientswith varicella were school children,
and could have acquired infection having mixed with
immigrant school children from Africa or Asia, thereby
accounting for genotypes A1 and A2 (Fig. 1). On the
other hand, it is notable that the novel genotypesB1 and
C1 occurred in adults with herpes zoster, two of whom
had a past history of varicella in childhood while living
in Ireland. This suggests that these novel genotypes
may have evolved independently. Unfortunately, VZV
isolates from previous years were unavailable to
ascertain if there has been a temporal change in the
composition of genotypes. Further study is needed to
investigate the epidemiology of VZV infections in
Ireland, in particular to determine if imported infec-
tions alone account for the genetic diversity of isolates
collected in Ireland.
Genotype A members are distinguished by the
possession of a BglI restriction site in gene 54 and are
particularly prevalent in individuals of African and
Asian descent [Quinlivan et al., 2002]. The novel T>G
mutation (SNP 95241) in ORF 54 characteristic of
genotype B1 would not be detected by PCR-RFLP. It is
conceivable that some of the BglI populations identi-
fied in previous studies employing solely restriction
enzyme analysis and not direct DNA sequencing may
have overlooked this SNP [Hawrami et al., 1997;
Quinlivan et al., 2002; Sauerbrei et al., 2003].
In contrast to the heterogeneity of VZVgenotypes, our
results indicate that VZV glycoprotein E (gE) epitopes
e1 and c1 are conserved in Irish clinical isolates. VZV-
MSP has an amino acid substitution in position 150 of
the surface glycoprotein gE, and has been shown to
have attributes consistent with increased virulence in
a mouse model [Santos et al., 2000]. In our study, a
919 bp fragment of the glycoprotein gE gene (ORF 68)
encompassing the non-synonymous mutation G>A at
codon 150 and the two epitopes e1 and c1 was sequenc-
ed. No non-synonymous mutations were detected,
although 50% of isolates had the synonymous nucleo-
tide polymorphism of T>C in codon 120 of ORF 68,
found in previous studies to be a common polymorphism
[Shankar et al., 2001; Faga et al., 2001]. It has been
suggested that antibody escape variant viruses like
VZV-MSP may arise from selective antibody pressure
over prolonged periods of time in immunocompromised
hosts [Ciurea et al., 2000]. Theseauthors found the same
amino acid substitution in laboratory-derived antibody
escape glycoprotein mutants as seen in the VZV-MSP
variant. However, no such mutant was found in our
study, which included 11 patients with herpes zoster,
four of whom were immunocompromised. It is possible
that VZV-MSP is a previously unrecognised subpopula-
tion of VZV that has been circulating for many years.
Whether it has increased replicative fitness is not
known. Larger studies need to be conducted to ascertain
the prevalence and clinical significance of this mutant
virus.
Our findings have implications for the model of
geographic isolation of VZV clades to certain regions as
the circulating Irish VZV population appears to com-
prise approximately equal numbers of each of the main
genotypes. This data are inconsistent with a model of
strict geographical separation of VZV genotypes [Faga
et al., 2001;Quinlivan et al., 2002;Wagenaar et al., 2003]
and suggests that VZV diversity in more pronounced in
certain areas than had been thought previously.
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